Medication Therapy for Methamphetamine Use Disorder
Currently, there is no FDA-approved pharmacotherapy for methamphetamine use disorder, and behavioral therapies remain the primary evidence-based treatment approach. 1
Current Evidence on Pharmacological Options
Most Promising Emerging Medications
The combination of extended-release injectable naltrexone plus extended-release oral bupropion (NTX + BUPN) shows the strongest recent evidence for reducing methamphetamine use. In the ADAPT-2 trial, participants receiving NTX + BUPN demonstrated a 27.1% increase in probability of testing negative for methamphetamine over 12 weeks, significantly greater than the 11.4% increase seen with placebo (difference of 15.8%, p=0.006) 2. Continued treatment beyond 6 weeks was associated with additional reductions in use up to 12 weeks 2.
Lisdexamfetamine (250 mg maintenance dose) demonstrates moderate efficacy during active treatment. A 2024 randomized controlled trial showed 8.8 fewer days of methamphetamine use over the 12-week treatment period (p=0.005), though evidence was weaker at the 13-week endpoint 3. Participants reported significantly greater treatment satisfaction (OR=3.80, p<0.001) and self-reported effectiveness (OR=2.89, p<0.001) 3. However, adverse events including nausea occurred, and 5% experienced serious adverse events 3.
Medications with Limited or Inconsistent Evidence
For acute withdrawal management, mirtazapine shows potential but inconsistent evidence. One trial found no significant differences in retention or symptom relief compared to placebo 4, while a 2023 review noted potential efficacy during acute withdrawal phases 5. Similarly, naltrexone and bupropion individually show mixed signals for withdrawal symptoms 5.
Topiramate demonstrates inconsistent evidence and is not recommended 5.
Recommended Treatment Approach
Primary Strategy: Behavioral Therapy
Cognitive behavioral therapy (CBT) combined with contingency management represents the evidence-based standard of care. A 2020 meta-analysis confirmed that combined CBT and pharmacotherapy outperforms usual care (effect size g=0.18-0.28) 6. For stimulant dependence specifically, contingency management shows superior efficacy compared to other psychosocial interventions 7.
Initiate intensive behavioral therapy immediately:
- CBT targeting cognitive, affective, and environmental risks
- Contingency management with structured rewards for abstinence
- Consider 12-step programs as adjunctive support (though evidence shows these are less effective than CBT or contingency management alone) 7
Pharmacotherapy Considerations
If pursuing pharmacological treatment despite lack of FDA approval:
First consideration: NTX + BUPN combination 2
- Extended-release injectable naltrexone (dosing per manufacturer guidelines)
- Plus extended-release oral bupropion (dosing per manufacturer guidelines)
- Monitor for 12 weeks minimum
- Contraindications: Seizure disorders (brain metastases, stroke history), current opioid use, MAO inhibitor use, closed-angle glaucoma
Alternative: Lisdexamfetamine 3
- 1-week induction to 250 mg
- 12-week maintenance at 250 mg
- 2-week taper
- Monitor for nausea and serious adverse events
- Requires close monitoring given stimulant properties
Critical Caveats
Important limitations to recognize:
- No medication has FDA approval for methamphetamine use disorder 1
- Behavioral therapies remain the primary evidence-based approach 1, 7
- The evidence for any pharmacotherapy is substantially weaker than for other substance use disorders (e.g., opioid or alcohol use disorder)
- Patient motivation and engagement in behavioral treatment predicts outcomes more strongly than medication choice
Do not use:
- Topiramate (inconsistent evidence) 5
- Mirtazapine as monotherapy (insufficient evidence) 4, 5
- Any medication without concurrent intensive behavioral therapy 6
Monitoring and Follow-up
Assess treatment response at:
- Week 2: Retention, adverse effects, engagement with behavioral therapy
- Week 6: Continued benefit assessment; consider discontinuation if no response
- Week 12: Primary endpoint for efficacy evaluation
- Ongoing: Urine drug screens twice weekly during active treatment 2
If treatment fails: Intensify behavioral interventions, consider referral to specialized addiction treatment center, and reassess for psychiatric comorbidities that may require treatment 1.